secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001104659-22-125054
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports 36% ORR in anti-PD1 failed melanoma; enters Roche collaboration for RP2/3
--------------------------------------------------------------------------------

- Collaboration with Roche to develop RP3 with atezolizumab/bevacizumab in 3L CRC and 1L/2L HCC; cost sharing; Phase 2 start H1 2023.
- IGNYTE anti-PD1 failed melanoma: 36% ORR, 20% CR rate in first 75 patients; 85% of responses ongoing; systemic activity seen.
- RP2/3 update: uveal melanoma 28.6% ORR (4/14 evaluable); soft tissue sarcoma 3/5 responding; responses durable.
- Phase 2 plans for RP2/3: SCCHN (130 patients), HCC (60), CRC (60); enrollment in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922125054/0001104659-22-125054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922125054/tm2232156d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-125054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer